Article Information
History
- December 1, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Vu Dinh Thiem, MD1,
- Dang Duc Anh, MD1,
- Vu Hai Ha, MD1,
- Nguyen Van Thom, MD2,
- Tran Cong Thang, MD3,
- Jose Mateus, PhD4,
- Juan Manuel Carreño, PhD5,6,
- Rama Raghunandan, PhD7,*,
- Nguyen Mai Huong, BPharm3,
- Laina D Mercer, PhD7,
- Jorge Flores, MD7,
- E Alexandar Escarrega, MS4,
- Ariel Raskin, BA5,6,
- Duong Huu Thai, MD8,
- Le Van Be, MD8,
- Alessandro Sette, Dr.Biol.Sc4,9,
- Bruce L Innis, MD7,
- Florian Krammer, PhD5,6,10,* and
- Daniela Weiskopf, PhD4,9,*
- 1National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Vietnam
- 2Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Vietnam
- 3PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Vietnam
- 4Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA
- 5Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA
- 6Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA
- 7Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
- 8Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Vietnam
- 9Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA, 92037, USA
- 10Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- ↵*Correspondence to:
Rama Raghunandan, mailto:rraghunandan{at}path.org, +1-301-793-6132, Florian Krammer, florian.krammer{at}mssm.edu, +1-212-241-8166, Daniela Weiskopf, daniela{at}lji.org, +1-858-752-6919
Posted December 01, 2023.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
3
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos